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ABSTRACT: Lipid-coated poly(lactide-co-glycolide) micropar-
ticles (LCMPs) consist of a solid polymer core wrapped by a
surface lipid bilayer. Previous studies demonstrated that
immunization with LCMPs surface-decorated with nanograms
of antigen elicit potent humoral immune responses in mice.
However, the mechanism of action for these vaccines remained
unclear, as LCMPs are too large to drain eﬃciently to lymph
nodes from the vaccination site. Here, we characterized the
stability of the lipid envelope of LCMPs and discovered that in
the presence of serum the lipid coating of the particles
spontaneously delaminates, shedding antigen-displaying vesicles.
Lipid delamination generated 180 nm liposomes in a temper-
ature- and lipid/serum-dependent manner. Vesicle shedding was restricted by inclusion of high-TM lipids or cholesterol in the
LCMP coating. Administration of LCMPs bearing stabilized lipid envelopes generated weaker antibody responses than those of
shedding-competent LCMPs, suggesting that in situ release of antigen-loaded vesicles plays a key role in the remarkable potency
of LCMPs as vaccine adjuvants.
■ INTRODUCTION
The development of vaccines based on subunit antigens,
recombinant proteins, polysaccharides, or peptide fragments
derived from pathogens, has led to increased safety but
decreased potency in vaccine candidates compared to that of
traditional live attenuated microbe vaccines. To increase the
immunogenicity of subunit vaccines, adjuvants play an
important role in vaccine development. Adjuvants are materials
that enhance immune responses elicited by vaccines either by
providing inﬂammatory signals (e.g., ligands for Toll-like
receptors1), modulating the delivery of antigen to immune
cells, or both.2 For example, antigen delivery can be altered by
providing a depot for long-term antigen release from a
vaccination site. Long-term biomolecule release is often
achieved by encapsulation of the cargo into a biodegradable
polymer matrix, such as poly(lactide-co-glycolide) (PLGA),
which is often employed because of its history of safe use in
humans, eﬃcient encapsulation of hydrophobic materials, and
tunable drug release behavior.3 However, delivery of protein
antigens encapsulated in PLGA micro- or nanoparticles is
challenging because of the low antigen encapsulation eﬃciency
and denaturation/aggregation of proteins during encapsulation
and release.4−6 Alternatively, antigen delivery can be modulated
at the single-cell level by surface-displaying antigens on the
surfaces of particulate carriers such as liposomes or polymer
particles. Surface display has been shown to enhance immune
responses, likely by increasing the degree of B-cell receptor
cross-linking and subsequent B-cell activation.7−13 Further-
more, incorporation into lipid particles has been previously
shown to be an eﬀective delivery method of lipophilic adjuvants
such as MPLA.14,15 Despite the disadvantages of degradable
polymers for use with protein antigen, these polymers remain
attractive for the slow-release co-delivery of inﬂammatory
adjuvant compounds that could shape the immune response
over time.16−19
In order to combine the surface display of antigen with a
biodegradable core in which we could ultimately co-deliver
additional adjuvant molecules, we recently described an
approach for synthesis of lipid-enveloped polymer micro-
particles and nanoparticles that present antigen bound to a
surface lipid bilayer.20 A self-assembled lipid bilayer coat
surrounding a PLGA core was achieved by using lipids as the
surfactant component of an emulsion/solvent evaporation-
based PLGA particle synthesis. The lipid bilayer was observed
to be a two-dimensionally ﬂuid surface that tightly envelops the
polymer core. We employed these lipid-coated microparticles
Received: March 4, 2014
Revised: May 31, 2014
Published: June 4, 2014
Article
pubs.acs.org/Biomac
© 2014 American Chemical Society 2475 dx.doi.org/10.1021/bm500337r | Biomacromolecules 2014, 15, 2475−2481
Terms of Use
(LCMPs) as vaccine delivery agents by conjugating protein
antigens to PEGylated lipids anchored in the bilayer coating
and co-incorporating adjuvant compounds such as the TLR
agonist monophosphoryl lipid A (MPLA) or α-galactosyl
ceramide in the particles. LCMPs elicited high, durable humoral
immune responses in response to injection of as little as 2.5 ng
of the model antigen ovalbumin (OVA) surfaced-displayed on
LCMPs.21 In addition, these particles triggered antigen-speciﬁc
proliferation of both CD4+ and CD8+ T-cells and production of
Th1-biased cytokines from T-cells in vivo.21 When formulated
as nanoparticles and functionalized with a candidate malaria
antigen VMP0001 and MPLA, lipid-coated particles were
shown to induce germinal center formation and elicited higher,
more durable antigen-speciﬁc titers of IgG antibodies of diverse
isotypes compared to those produced by vaccination with
soluble VMP001 and MPLA.22
Despite the eﬃcacious nature of these lipid-coated particles,
it was unclear how they presented antigen to the immune
system, particularly in the case of LCMPs, because these
microparticles (diameter, 2.6 ± 1.2 μm) did not freely drain to
lymph nodes.23 However, during initial cryo-TEM character-
ization studies on the LCMPs, we observed that over time the
lipid bilayers at the surface of the biodegradable particles begin
to delaminate from the polymer core.20 This observation of
delamination suggested that the lipid bilayer might not be
stable on the PLGA particle cores over time. Since antigen was
conjugated to the lipid bilayer, we hypothesized that
delamination of the lipid envelope could play a role in the
adjuvant characteristics of LCMPs.
Here, we directly evaluated the stability of the bilayer coating
of LCMPs and examined the role of bilayer delamination in the
immunogenicity of this particulate vaccine system. We found
that under physiological conditions LCMPs exhibit rapid
bilayer delamination, leading to the release of antigen-bearing
lipid vesicles. We evaluated the kinetics of bilayer shedding and
the resulting eﬀects on the immunogenicity of LCMPs in vivo.
In addition, we explored the kinetic dependence of lipid
delamination on the presence of lipid/serum in the surrounding
environment. To test the hypothesis that delamination impacts
immunogenicity, stabilized-bilayer LCMPs were developed
either by the inclusion in the lipid bilayer of cholesterol or
lipids with saturated carbon chains. Mice immunized with
OVA−LCMPs generated higher anti-OVA titers than mice
immunized with stabilized-bilayer OVA−LCMPs or OVA on
delaminated lipid vesicles (DLVs) alone. These results suggest
that the in situ release of delaminated lipid vesicles enhances
humoral immune responses to surface-displayed antigen, with
LCMPs acting as a source of in situ generated antigen-bearing
liposomes following injection.
■ MATERIALS AND METHODS
Materials. All lipids, 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dioleoyl-sn-glycero-3-phoshpo-(1′-rac-gylcerol)
(DOPG), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(poly-
(ethylene glycol))2000] (DSPE-PEG2K-maleimide), 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(14:0 Liss-Rhod-DOPE), 1,2-distearoyl-sn-glycero-3-phospohethanol-
amine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DSPE), and choles-
terol, were purchased from Avanti Polar Lipids (Alabaster, AL).
Poly(lactic-co-glycolic acid) (PLGA) with a 50:50 ratio of lactic acid
and glycolic acid and an inherent viscosity of 0.42 dL/G was purchased
from Evonik Corporation (Birmingham, AL). Monophosphoryl lipid A
(MPLA, from Salmonella enterica serotype minnesota Re 595, cat. no.
L6895) and solvents were purchased from Sigma-Aldrich (St. Louis,
MO). N-Succinimidyl S-acetyl(thiotetraethylene glycol) (SAT(PEG)4)
was purchased from Pierce Biotechnology (Rockford, IL). Puriﬁed
ovalbumin (OVA) was purchased from Worthington Biochemical
(Lakewood, NJ) and subsequently passed through detoxi-gel
endotoxin-removing columns (Pierce Biotechnology, Rockford, IL)
to remove any trace endotoxin.
Synthesis of Lipid-Coated Microparticles (LCMPs). Micro-
particles consisting of a PLGA core and lipid bilayer envelope were
synthesized as previously reported.20,24 Brieﬂy, 5 mg of lipid in a
72:18:10 DOPC/DOPG/DSPE-PEG2K-maleimide molar ratio (for
DOPC−LCMPs) or a 75:16:9 DSPC/DOPG/DSPE-PEG2K-malei-
mide molar ratio (for DSPC−LCMPs) was dried under nitrogen
followed by incubation under vacuum at 25 °C for 18 h. The resulting
lipid ﬁlm was dissolved in dichloromethane (DCM) containing PLGA
for a ﬁnal polymer/lipid weight ratio of 16:1. This organic solution was
emulsiﬁed into distilled deionized ultrapure water by homogenization
at a ratio of 8:1 aqueous phase/organic phase, stirred for 12 h at 25 °C
to remove DCM by evaporation, and passed through a 40 μm ﬁlter.
Microparticles were isolated from the resulting polydisperse samples
by two centrifugation steps at 1100 rcf for 1 min each, with removal of
the supernatant and resuspension into pH 7.4 PBS following each
centrifugation step. Particle size distributions were determined using
the Horiba Partica LA-950 V2 laser diﬀraction particle size analysis
system.
Synthesis of Liposomes. Liposomes prepared with a 72:18:10
molar ratio of DOPC/DOPG/DSPE-PEG2K-maleimide were used for
immunization studies, and vesicles with an 80:20 molar ratio of
DOPC/DOPG were used for in vitro lipid delamination studies. Lipid
ﬁlms dried as described above were resuspended in pH 7.4 PBS,
vortexed for 30 s every 10 min for 1 h, subjected to six freeze−thaw
cycles in liquid nitrogen and a 37 °C water bath, and extruded for 21
passes through a 200 nm pore polycarbonate membrane (Whatman
Inc., Sanford, ME). Vesicle sizes were determined by dynamic light
scattering (Brookhavenn 90 Plus particle size analyzer, Worcetershire,
UK). Liposomes were stored at 4 °C until use.
Antigen Conjugation onto Lipid-Enveloped Particles and
Liposomes. Thiolated OVA was conjugated to the surface of
maleimide-functionalized lipid-enveloped particles or liposomes as
previously described.24 In brief, endotoxin-free OVA was function-
alized with the heterobifunctional cross-linker SAT(PEG)4 (Pierce
Biotechnology, Rockford, IL), which was then deacetylated to expose
sulfhydryl groups following the manufacturer’s instructions. Following
buﬀer exchange into 10 mM EDTA (pH 7.4), via 7000 MWCO Zeba
spin desalting columns (Pierce Biotechnology, Rockford, IL), thiolated
OVA (5 mg/mL) was incubated with particles (70 mg/mL) or
liposomes (3 mg/mL) at 25 °C for 4 h (for particles) or overnight (for
liposomes). To remove unbound antigen, particles were washed three
times by centrifugation for 5 min at 10 000 rcf with pH 7.4 PBS, and
liposomes were washed three times by centrifugation in 30 kDa
MWCO Vivaspin columns (Vivaproducts, Littleton, MA). The
amount of OVA coupled was determined by solubilizing lipids from
the particles/vesicles in 30 mM Triton X-100 and measuring the
quantity of OVA by enzyme-linked immunosorbent assay (ELISA).
Particles and liposomes were stored at 4 °C until use, which was within
4 h for immunization experiments and 48 h for in vitro experiments.
Analysis of Lipid Delamination from LCMPs. Particles were
synthesized as described above, incorporating 2 mol % of 14:0 Rhod-
DOPE (for DOPC−LCMPs) or NBD-DSPE (for DSPC−LCMPs) in
the lipid composition. For characterization of the delamination of
protein antigen displayed on the lipid envelope, OVA was conjugated
to lipid-enveloped particles as described above. Postsynthesis, particles
were washed three times by centrifugation at 5000 rcf for 5 min and
subsequent suspension in pH 7.4 PBS. After the third wash, particles
were suspended at 12 mg/mL in pH 7.4 PBS, fetal bovine serum, or 10
mM 80:20 DOPC/DOPG liposomes in pH 7.4 PBS, divided into 150
uL aliquots in separate eppendorf tubes for each time point/replicate,
and incubated with rotation at 37 °C. At each time point, replicate
aliquots were centrifuged for 20 min at 16 100 rcf, and the resulting
supernatant was collected for analysis. Lipid release from the LCMPs
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was determined by adding 30 mM Triton X-100 to the supernatants,
measuring rhod-DOPE ﬂuorescence in a ﬂuorescence plate reader
(Tecan Inﬁnite M200 Pro, Man̈nedorf, Switzerland), and normalizing
to the total amount of ﬂuorescent lipid present. OVA released from
particles was determined by anti-ovalbumin ELISA on the super-
natants of the particle aliquots, and the values were normalized to the
total amount of OVA−lipid present. This total amount of lipid per
aliquot was determined in ﬂuorescently tagged samples by addition of
Triton to three or four standard aliquots, which were incubated at 55
°C and subsequently vortexed and sonicated for 1 min each prior to
centrifugation for 15 min at 16 100 rcf followed by ﬂuorescent-based
quantiﬁcation of the supernatant. To determine the total amount of
the antigen, OVA, released from DOPC−LCMPs particles, the same
procedure as above was employed without the 55 °C incubation step
and with ELISA-based quantiﬁcation. The 55 °C incubation step is
unnecessary for lipid delamination from DOPC−LCMPs and
therefore was omitted to prevent any degradation of the OVA protein.
Size Characterization of Delaminated Lipid Vesicles.
DOPC−LCMPs were prepared and incubated at 37 °C in pH 7.4
PBS for 7 days, after which the microparticles were pelleted via a 30
min centrifugation step at 16 100 rcf. The size distribution of DLVs in
the supernatant was determined by laser diﬀraction as described above.
Animal Studies. All animal experiments were conducted under an
IUCAC approved protocol in accordance with local, state, and NIH
animal care and use guidelines. Immunizations were carried out on
female BALB/c mice, 6 to 7 weeks of age, purchased from Jackson
Laboratories. Immediately prior to immunization, 1.3 μg of the TLR-4
agonist, MPLA, per 50 μL was mixed with 10 ng of OVA conjugated
to LCMPs, DLVs, or liposomes in sterile pH 7.4 PBS, following
postsynthesis insertion techniques described previously.21,25 Mice were
immunized by injection of 50 μL solutions s.c. at the tail base and were
boosted 14 days later. Serum samples were collected on a weekly basis
for analysis of serum antibody titers.
Antibody Titer Measurements. Serum total IgG titers, isotype
IgG1 and IgG2A titers, and avidity indices were determined as
previously described.24 Brieﬂy, 96-well plates were coated with OVA,
blocked with bovine serum albumin, incubated with serially diluted
serum, and detected with HRP-labeled antimouse IgG, IgG1, or IgG2A
(Bio-Rad) followed by development and measurement of optical
absorbance at 450 nm. Antibody titer is reported as reciprocal serum
dilution at an absorbance of 0.5. For avidity indices, duplicate serum
dilutions were prepared for each sample, and for one set of dilutions,
wells were incubated for 10 min with 6 M urea prior to detection with
the respective anti-mouse secondary antibody. The avidity index is
reported as the ratio of the titers of the urea-treated sample to those of
the non-urea-treated sample.
Statistical Analysis. Statistical analyses were performed using
GraphPad Prism software. Comparisons of formulations over time
were performed using two-way ANOVA tests, and comparisons of
multiple formulations at a single time point were performed using one-
way ANOVA tests. Two-tailed unpaired Student t tests were used to
determine statistical signiﬁcance between two experimental groups for
all other data.
■ RESULTS AND DISCUSSION
Shedding of Lipid Vesicles from LCMPs. We previously
reported that phospholipids incorporated into PLGA particles
during an emulsion/solvent evaporation synthesis segregate to
the surface of nascent particles, self-assembling into a lipid
envelope surrounding the polymer core (Figure 1A). When
these particles were incubated in pH 7.4 PBS at 37 °C for 7
days to permit partial hydrolysis of the biodegradable particle
core, cryo-TEM imaging revealed evidence of delamination of
lipid bilayers from the particle surfaces, which was observed
even in the absence of added MPLA, suggesting that adjuvant
incorporation did not induce this eﬀect.20 This ﬁnding
suggested that lipids might be shed from LCMPs by “budding”
of lipid bilayers from the particles over time (Figure 1A). This
might be particularly promoted in vivo, as serum albumin and
lipoproteins are known to extract lipid from ﬂuid bilayers.26−28
To directly test this hypothesis, LCMPs with a diameter of 2.54
± 0.95 μm (Figure 1B) were incubated in PBS at 37 °C for 1
week. After this incubation time, the PLGA particle cores were
still macroscopically intact,20 and the size distribution of the
particles recovered by centrifugation was essentially unchanged
from that of the starting material (data not shown). However,
analysis of the supernatant by laser diﬀraction to detect released
lipid vesicles revealed nanoparticles with a mean size of 176 ± 6
nm in the LCMP supernatants (Figure 1C). These particles
were not PLGA fragments, as neat PLGA nanoparticles of this
size prepared independently were pelleted by the centrifugation
step used to remove LCMPs from the supernatants in this
experiment. To verify that these nanoparticles in the LCMP
supernatant were in fact lipid vesicles, we prepared particles
containing a rhodamine-tagged lipid tracer in the bilayer
coating. Fluorescence measurements on the supernatant
collected from LCMPs incubated 7 days in PBS at 37 °C
showed the release of 54 ± 11% of the total lipid tracer into the
supernatant, conﬁrming the release of delaminated lipid vesicles
(DLVs) from the microparticles over time.
We next characterized the kinetics of DLV shedding from
LCMPs. Microparticles containing rhodamine-labeled lipid
were incubated in PBS and DLVs released into the supernatants
over time were detected by ﬂuorescence spectroscopy. As
shown in Figure 2A, although lipids remained stably associated
with LCMPs at 4 °C, vesicles were rapidly shed from the
particles at 37 °C in PBS, with delamination reaching a plateau
after 24 h. To test the eﬀect of serum on lipid delamination
kinetics, LCMPs containing rhodamine-conjugated lipid were
incubated in either serum or PBS, and delamination was
quantiﬁed as before. Figure 2A shows that serum increased the
fraction of delaminated lipid by 1.6-fold, with substantial vesicle
shedding within 4 h that continued slowly through 48 h. We
hypothesized that interactions of the lipid surface layers with
lipid droplets in serum may be a major contributor to vesicle
Figure 1. (A) Schematic structure of as-synthesized LCMPS with
surface-conjugated protein antigen and vesicles “budded” from PLGA
polymer core, forming delaminated-lipid vesicles (DLVs). (B) Size
distribution of freshly synthesized microparticles after wash steps
determined by laser diﬀraction. (C) Size distribution of delaminated
vesicles released from LCMPs after 7 days in PBS at 37 °C determined
by laser diﬀraction.
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delamination, as the adsorption of lipids by serum lipoprotein
particles is essential for lipid transport in vivo.29 Previous studies
have shown that liposomes are destabilized in the presence of
serum because of the transfer of phospholipids to lip-
oproteins.26,27,30 To model interactions of LCMPs with lipids
in serum, a group of microparticles was incubated in PBS
containing 10 mM of 200 nm diameter synthetic 4:1 DOPC/
DOPG liposomes. The results indicate that the inclusion of
liposomes in the aqueous buﬀer replicates the kinetics of lipid
delamination in serum (Figure 2B), suggesting that the
presence of environmental lipid promotes DLV delamination
from LCMPs.
LCMPs carrying protein antigen covalently linked to the
membrane (e.g., as illustrated in Figure 1A) elicit robust
humoral immune responses in vivo.22,24 To test whether antigen
conjugated to the lipid coat is transferred to delaminating
vesicles, thiol-functionalized OVA was conjugated to malei-
mide-functionalized PEG chains incorporated into the particle
bilayer coating, and its release over time into serum at 37 °C
was quantiﬁed by ELISA. As expected, lipid-conjugated OVA
was shed from the LCMPs with kinetics matching rhodamine-
labeled lipid delamination (Figure 2C). Altogether, these data
suggest that LCMPs rapidly shed submicrometer liposomes
under conditions mimicking interstitial ﬂuid to which the
particles would be exposed during immunization in vivo.
Delaminated Vesicles Prime Antibody Responses
Nearly Equivalent to Those of LCMPs. Given the rapid
shedding of liposomes from LCMPs in the presence of serum,
we hypothesized that vesicles spontaneously released from the
microparticles following injection could play an important role
in the immunogenicity of LCMP vaccines. To explore this
possibility, we prepared OVA-conjugated LCMPs and
incubated a fraction of the particles at 37 °C in PBS to induce
delamination, followed by collection of the supernatant
containing shed vesicles. The concentration of antigen in the
shed vesicle preparation was measured by ELISA, and mice
were then immunized with MPLA mixed with 10 ng of OVA
carried by puriﬁed delaminated vesicles or the parent
(nondelaminated) particle fraction. In addition, a third group
of mice were immunized with OVA-conjugated pure liposomes
prepared with the same lipid composition as the LCMPs to
control for possible changes in the lipid structure or
composition occurring during budding of vesicles from the
PLGA-core particles. Each group of mice was boosted on day
14 with identical formulations, and serum was collected over
time for analysis of titers of anti-OVA IgG. As shown in Figure
3A,B, DLVs and the control synthetic liposomes elicited
essentially identical OVA-speciﬁc IgG responses. Both lip-
osomal vaccines were somewhat less immunogenic than that of
intact LCMPs, eliciting average antibody titers 2-fold lower
than LCMPs. However, DLVs were still capable of priming a
strong immune response to this low dose of OVA, which
Figure 2. Kinetics of lipid delamination from LCMPs in vitro determined by monitoring release of ﬂuorescently labeled lipid tracer (A−C) or PEG-
lipid-conjugated OVA (C) into the supernatants of particles over time. (A) Release of rhodamine-lipid into the supernatant of LCMP particles was
assessed as a function of temperature in pH 7.4 PBS or 100% fetal bovine serum (p < 0.0001 comparing 37 °C serum to 37 °C PBS, 4 °C serum to 4
°C PBS, 37 °C serum to 4 °C serum, and 37 °C PBS to 4 °C PBS). (B) Lipid release kinetics for rhodamine-lipid-labeled LCMPs incubated in PBS
containing 10 mM unlabeled DOPC/DOPG liposomes at 37 °C. (C) LCMPs conjugated with OVA protein were incubated in 100% fetal bovine
serum at 37 °C, and OVA accumulation in the supernatant was assessed over time by ELISA analysis of LCMP supernatants.
Figure 3. (A−D) BALB/c mice (n = 6/group) were immunized s.c.
with 10 ng of OVA displayed on lipid-enveloped microparticles
(LCMPs), delaminated lipid vesicles (DLVs) collected from LCMPs,
or pure liposomes and were boosted with identical formulations on
day 14. Liposomal vaccines are compared to control immunizations
with soluble OVA. In all particle formulations, 1.3 μg of MPLA per
injection was included. (A) Mean end-point OVA-speciﬁc IgG serum
titers on day 21 (***, p < 0.001). (B) Mean end point OVA-speciﬁc
IgG serum titers over time (p = 0.006 for formulation over time). (C)
OVA-speciﬁc IgG1 and IgG2A isotype serum titers at day 21 (*, p <
0.05; **, p < 0.01; ***, p < 0.001). (D) Ratio of post boost peak (day
28) end-point OVA-speciﬁc IgG2A to IgG1 serum titers.
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elicited undetectable anti-OVA titers in three out of four
animals when administered as a soluble vaccine mixed with
MPLA (Figure 3A). Titers in all three particle immunization
groups were maintained over at least 70 days post priming.
Although DLVs elicited weaker OVA-speciﬁc IgG1 and IgG2A
antibodies than those elicited by parent LCMPs (Figure 3C),
both groups exhibited identical IgG2A/IgG1 ratios (Figure 3D).
As IgG2A is considered to be indicative of “Th1-like” responses
and IgG1, “Th2-like” responses, this result suggests both the
lipid-coated microparticles and shed liposomes primed bal-
anced Th1/Th2 responses and that the small diﬀerence in titers
comparing LCMPs and shed vesicles reﬂects a diﬀerence in
strength of priming rather than diﬀerent Th-biasing of the
antibody response. Altogether, these data suggest that
delamination of antigen-bearing liposomes plays a critical role
in the immune response primed by LCMPs carrying surface-
bound antigens.
Immunogenicity of Stabilized-Envelope LCMPs.
Although Figure 3 demonstrates that in vitro generated DLVs
induced slightly lower antibody titers than those by parental
LCMPs, it remained unclear whether in vivo budding of
antigen-carrying vesicles from the microparticles was necessary
for the high immunogenicity of the lipid-coated microparticles.
If in vivo delamination were essential, then LCMPs that failed to
undergo lipid delamination would be expected to prime weaker
immune responses. To test this hypothesis, we sought to
prepare LCMPs with lipid envelopes stabilized against
delamination. We tested two strategies to create such
stabilized-envelope particles: incorporation of high-TM lipid
and incorporation of cholesterol into the lipid coating.
Phospholipids with high melting temperatures have few/no
unsaturated bonds in their acyl tails, allowing the lipids to pack
tightly and favoring formation of liquid crystalline gel phases. In
addition, the removal of double bonds in the acyl chains of
phospholipids in vesicles reduces the rates of lipid transfer from
liposomes to serum lipoproteins by 4-fold.31 Therefore, DSPC
(TM = 55 °C) was used in place of DOPC (TM = −20 °C) to
generate high-TM DSPC−LCMPs. In vitro, inclusion of high-TM
lipid did not block vesicle shedding completely but did lower
the fraction of lipid lost from the particles in the presence of
serum by 33%, as shown in Figure 4A. We tested whether the
reduced shedding of vesicles would impact the immunogenicity
of these particles compared to that of DOPC-based LCMPs.
BALB/c mice were immunized s.c. on days 0 and 14 with
MPLA mixed with DOPC−LCMPs or DSPC−LCMPs each
carrying 10 ng of OVA. As shown in Figure 4B, despite the
modest reduction in lipid shedding exhibited by DSPC−
LCMPs, the immunogenicity of these particles was signiﬁcantly
altered, as mice immunized with DSPC−LCMPs showed a 3.5-
fold reduction in titers of OVA-speciﬁc antibodies compared to
those from DOPC−LCMPs at 1 week post boost (Figure 4B).
Futhermore, DSPC−LCMPs elicited 64 ± 10% lower total
OVA-speciﬁc IgG titers (p = 0.0023, Figure 4C) and lower
serum IgG1 titers at the post boost peak on day 21 (p = 0.0067,
Figure 4D) when compared to those of DOPC−LCMPs.
Interestingly, the avidity index of the antibody response elicited
by DSPC−LCMPs was higher than that of the response primed
by to DOPC−LCMPs from day 28 onward (p = 0.0491
comparing the two groups over time). However, the overall
strength of the antibody response elicited by LCMPs was
reduced when vesicle shedding was impeded by incorporation
of high-TM lipids.
To further test the idea that vesicle budding from antigen-
conjugated LCMPs is important for their immunogenicity, we
Figure 4. LCMPs prepared with high-TM lipids show reduced vesicle shedding and weaker antibody responses in vivo. (A) Kinetics of in vitro lipid
release from high-TM lipid-enveloped microparticles (DSPC−LCMPs) or regular, low-TM lipid microparticles (DOPC−LCMPs) in serum,
determined by following ﬂuorescent lipid tracer released into particle supernatants upon incubation with FBS at 37 °C (p < 0.0001). (B−E) BALB/c
mice (n = 5) were immunized on days 0 and 14 with 1.3 μg of MPLA mixed with DOPC−LCMPs or DSPC−LCMPs, each conjugated with 10 ng of
OVA. (B) OVA-speciﬁc antibodies detected by ELISA as a function of serum dilution at the post boost peak, day 21 (p < 0.0001). (C) Mean OVA-
speciﬁc IgG serum titers on days 21, 38, and 45 (DOPC−LCMPs vs DSPE−LCMPs over time, p = 0.0023). (D) OVA-speciﬁc IgG1 and IgG2A
isotype serum titers at day 21 (DOPC IgG1 vs DSPE IgG1, *, p = 0.0067). (E) Mean OVA-speciﬁc IgG avidity indices as a function of time (p =
0.0491).
Biomacromolecules Article
dx.doi.org/10.1021/bm500337r | Biomacromolecules 2014, 15, 2475−24812479
also tested a second strategy for inhibiting liposome shedding
from the microparticles. Cholesterol is a major component of
cell membranes and is often used as a stabilizing agent in lipid
vesicle preparations because it orders and condenses ﬂuid-phase
bilayers.32−34 Thus, we hypothesized that cholesterol, like high-
TM lipids, could also act to stabilize the lipid bilayer of LCMPs.
We prepared DOPC−LCMPs incorporating 0, 1, or 10 mg of
cholesterol per 80 mg of PLGA. In vitro, DLV formation was
not inhibited completely by the inclusion of cholesterol, but
delamination did decrease with increasing cholesterol quantity.
As shown in Figure 5A,B, increasing the amount of cholesterol
incorporated in the particles lowered the fraction of lipid shed
into solution from LCMPs, although the eﬀect was less
pronounced in serum than in PBS, perhaps because of
cholesterol absorption by lipoprotein particles in serum. As
with the high-TM lipid LCMPs, we tested the immunogenicity
of LCMPs with cholesterol by vaccinating BALB/c mice. A plot
of mean OVA-speciﬁc IgG end-point titers shows decreased
immunogenicity (up to a 2.5-fold average drop in titers) with
increasing cholesterol content (Figure 5C) (comparison of 10
vs 1 mg titer over time, p < 0.001). An analysis of IgG1 and
IgG2A isotype titers at the post boost peak indicates that IgG1
titers are also inversely dependent on cholesterol quantity;
however, IgG2A isotype titers remained relatively independent
of cholesterol presence (Figure 5D). Interestingly, avidity
indices were independent of cholesterol incorporation in the
particles (data not shown). Thus, using a second strategy to
stabilize the lipid bilayer of LCMPs by altering its composition,
we found a similar reduction in antibody responses when
vesicle shedding was inhibited.
The agreement in results obtained by these two diﬀerent
strategies for physically stabilizing the bilayer suggests that the
reduced immunogenicity observed with DSPC−LCMPs or
chol/DOPC−LCMPs when compared to that with DOPC−
LCMPs is not due to the chemical alterations in the bilayer
composition. The antibody response to LCMPs was not
entirely ablated by inhibiting vesicle delamination, but the
reduced response is all the more striking given the fact that the
lipid bilayer composition-based strategies we tested here for
blocking DLV release from the particles were at best only
∼30% eﬀective under conditions mimicking exposure to serum
components. Furthermore, the immunogenicity of liposomes is
inversely proportional to membrane ﬂuidity, and it has been
speciﬁcally shown that inclusion of cholesterol or high-TM lipid
in liposome vaccine formulations increases immunogenicity.35
Thus, an enhancement derived from decreased membrane
ﬂuidity of shedded liposomes may be masking the full impact
that decreased delamination from LCMPs has on humoral
antibody responses. Altogether, these results are consistent with
vesicle shedding from LCMPs playing an important role in the
priming of humoral responses by these microparticle vaccines.
An advantage of this system is the 180 nm diameter of DLVs, as
nanoparticles in this size range are well-suited for delivery to
lymph nodes via subcutaneous injection and direct draining
into the lymphatic system.36 Furthermore, antigen that drains
freely to lymph nodes can interact directly with B-cells, which
generates optimal humoral immune responses.37
Coupling the observed reduction in immunogenicity from
lipid-stabilized LCMPs with the in vitro observation of identical
delamination kinetics of LCMPs in serum or in 10 mM
liposome buﬀer leads to the possibility that antigen conjugated
to lipid on LCMPs may be taken up by lipoprotein particles in
vivo. This uptake and subsequent circulation throughout the
lymphatic system could account for the enhanced immunoge-
nicity of LCMPs over stabilized-lipid bilayer MPs or synthetic
liposomes. Prior work characterizing the lipid transfer between
liposomes and lipoproteins further supports this concept,
especially as inclusion of cholesterol in liposome formulations
Figure 5. Cholesterol was included in the lipid bilayer of LCMPs to decrease delamination of the envelope. (A, B) Kinetics of lipid release, in PBS
(A) or fetal bovine serum (B), of LCMPs, which were synthesized with 0, 1, or 10 mg of cholesterol (per standard 80 mg PLGA batch).
Delamination was quantiﬁed by the ﬂuorescent detection of rhodamine-lipid in the supernatant of aliquots of pelleted microparticles. (A: p < 0.0001;
B: p < 0.0001 for eﬀect of cholesterol over time.) (C, D) BALB/c mice (n = 5) were immunized and boosted 14 days later with 10 ng of OVA
conjugated to the surface of LCMPs containing 0, 1, of 10 mg of cholesterol per batch. In all formulations, 1.3 μg of MPLA per mouse was
incorporated into the lipid bilayer. (C) Mean end-point ELISA-based OVA-speciﬁc IgG serum titers over time (comparison of 10 vs 1 mg titer over
time, p < 0.0001). (D) End-point OVA-speciﬁc IgG1 and IgG2A isotype serum titers at day 28, the post boost peak (*, p < 0.05; **, p < 0.01).
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was shown to decrease the rate of lipid transfer to
lipoproteins.30 These results are consistent with our observa-
tion of decreased immunogenicity of LCMPs with increasing
cholesterol inclusion.
■ CONCLUSIONS
Here, we have explored the mechanisms underlying the potent
immunogenicity of lipid-coated biodegradable microparticles in
vaccine delivery. We found that although these particles are too
large to eﬃciently drain from subcutaneous injection sites to
lymph nodes, they are still very eﬀective in antigen delivery
because of the spontaneous shedding of antigen-bearing lipid
vesicles from the particle surfaces, which occurs rapidly under
physiological conditions. Changes in lipid composition that
reduce microparticle surface vesicle budding lowered the
immunogenicity of the particles in vivo, suggesting that this
mechanism is important for the eﬀectiveness of these antigen
delivery vehicles. This antigen-bearing vesicle release combined
with molecular adjuvants either incorporated in the membranes
(as shown here) or encapsulated in the PLGA particle core and
slow-released at the injection site to drain to local lymph
nodes16−19 could provide an eﬀective strategy for enhancing the
immunogenicity of subunit vaccines.
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